A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05543629
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986442 — BIOLOGICAL
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified days
  • Docetaxel — DRUG
    Specified dose on specified days
  • Carboplatin — DRUG
    Specified dose on specified days
  • Pemexetred — DRUG
    Specified dose on specified days
  • Paclitaxel — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.

Key Dates

Start date
Oct 4, 2022
Status verified
Feb 2025
Primary completion
Sep 12, 2024
Completion
Sep 12, 2024

Study Design

Enrollment
36 participants (actual)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A: BMS-986442 + Nivolumab
  • Experimental: Part B1: BMS-986442 + Nivolumab
    Second line (2L) + Post-immuno-oncology (IO)/Platinum-Doublet Non-small cell lung cancer (NSCLC)
  • Experimental: Part B2: BMS-986442 + Nivolumab
    Post IO Gastric Cancer/Gastroesophageal Junction and Post-IO squamous cell carcinoma of the head and neck (SCCHN)
  • Experimental: Part C: BMS-986442 + Nivolumab + Docetaxel
  • Experimental: Part D: BMS-986442 + Nivolumab + Carboplatin + Pemetrexed
  • Experimental: Part E: BMS-986442 + Nivolumab + Carboplatin + Paclitaxel

Primary Outcome Measure

Number of Participants With Adverse Events [ Time Frame: From first dose to 100 days post last dose (Approximately 6 Months) ]

Locations (14)

FacilityCityStateZIPSite coordinators
Mayo Clinic in Arizona - PhoenixPhoenixArizona85054-
Local Institution - 0096Costa MesaCalifornia92627-
Local Institution - 0075OrangeCalifornia92868-3201-
Mayo Clinic in FloridaJacksonvilleFlorida32224-
Local Institution - 0027OrlandoFlorida32804-
Local Institution - 0029Fort WayneIndiana46804-
Local Institution - 0022New OrleansLouisiana70121-
Local Institution - 0005Grand RapidsMichigan49546-
Mayo Clinic in Rochester, MinnesotaRochesterMinnesota55905-
Local Institution - 0003HackensackNew Jersey07601-
Carolina BioOncology InstituteHuntersvilleNorth Carolina28078-
Local Institution - 0019CincinnatiOhio45219-
Local Institution - 0046AllentownPennsylvania18103-
Local Institution - 0016HoustonTexas77030-

Related coverage on Hipa.ai

Find similar trials in Phoenix, AZ

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Mayo Clinic in Arizona - Phoenix· Phoenix, AZLocal Institution - 0096· Costa Mesa, CALocal Institution - 0075· Orange, CAMayo Clinic in Florida· Jacksonville, FLLocal Institution - 0027· Orlando, FLLocal Institution - 0029· Fort Wayne, IN

Related Studies